Trials / Active Not Recruiting
Active Not RecruitingNCT07046182
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To observe the efficacy and safety of the CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CEP + Dasatinib + Azacitidine | CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma |
Timeline
- Start date
- 2023-10-21
- Primary completion
- 2028-05-26
- Completion
- 2028-05-26
- First posted
- 2025-07-01
- Last updated
- 2025-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07046182. Inclusion in this directory is not an endorsement.